Thane, Maharashtra, India, October 2025 — Inventia Healthcare Limited has announced the appointment of Mehul Patel as Head of R&D, Technology Transfer, and Regulatory Affairs, reinforcing the company’s commitment to advancing research, innovation, and regulatory excellence.
With over 20 years of leadership experience in formulation development and pharmaceutical innovation, Mehul brings extensive expertise across generic oral drug products, modified-release formulations, and regulated markets such as the USA, Europe, and Canada.
Most recently, he served as Sr. Vice President – R&D at S Kant Healthcare Ltd., where he oversaw R&D operations, including formulation development, technology transfer, analytical development, project management, and regulatory affairs for solid oral, liquid oral, and topical dosage forms.
Prior to that, Mehul spent more than 13 years at Macleods Pharmaceuticals Ltd., rising to Vice President and Assistant Vice President roles, where he led formulation development, regulatory filings, and post-approval process improvements across multiple product categories. His leadership significantly enhanced the company’s R&D output and global market compliance.
Earlier in his career, Mehul worked with leading pharmaceutical organizations including Sun Pharma, Morepen Laboratories Limited, Astron Research Ltd., and Zydus Group, where he gained hands-on experience in complex formulations such as soft gelatin, pellet-based products, oncology, and hormone therapies. His proven track record includes expertise in scale-up, QbD, process validation, lifecycle management, and technology transfer in CDMO/CMO environments.
At Inventia Healthcare, Mehul will play a critical role in driving R&D innovation, strengthening regulatory frameworks, and advancing the company’s global expansion in international pharmaceutical markets. His appointment underscores Inventia’s focus on innovation, quality, and patient-centric solutions.
About Inventia Healthcare Limited
Inventia Healthcare Limited, established in 1985, is a privately held pharmaceutical development and manufacturing company headquartered in Mumbai, India. Dedicated to developing complex generics and novel innovative products, Inventia partners with mid-sized firms, large local players, and multinational companies worldwide, offering end-to-end solutions from research and development to commercialization.
With a world-class pharmaceutical and technology centre and a fully compliant production facility at MIDC Ambernath, Inventia has expanded its presence to over 50 countries globally. The company remains committed to innovation, product quality, and long-term strategic partnerships that enhance patient compliance and healthcare outcomes.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
